Helping Your Patients Navigate Climara Supply Challenges

Your patients depend on you when they can't fill their Climara prescription. As supply disruptions for estradiol transdermal patches continue into 2026, providers play a critical role in ensuring treatment continuity. This guide offers practical, actionable strategies to help your patients find Climara — or a suitable alternative — as quickly as possible.

Understanding the Current Landscape

Climara (estradiol transdermal system) is manufactured by 3M Drug Delivery Systems for Bayer HealthCare Pharmaceuticals. It is a once-weekly patch available in six strengths (0.025 to 0.1 mg/day). The product has faced intermittent availability issues due to manufacturing complexity, increased HRT demand, and raw material constraints.

For a detailed clinical overview of the shortage, see our companion article: Climara shortage: What providers and prescribers need to know in 2026.

Strategy 1: Direct Patients to MedFinder

MedFinder for Providers is a free tool that helps locate medications at pharmacies with current stock. You can:

• Search for Climara or generic estradiol patches by strength and zip code
• Share search results directly with patients
• Integrate MedFinder into your patient communication workflow

Recommending MedFinder at the point of prescribing — especially when you anticipate availability challenges — gives patients a head start on filling their prescription.

Strategy 2: Write Flexible Prescriptions

One of the most impactful steps you can take is writing prescriptions that maximize the pharmacist's ability to fill them:

• Allow generic substitution: Unless clinically necessary, do not mark prescriptions as "dispense as written." AB-rated generic estradiol patches are therapeutically equivalent to Climara.
• Specify the daily dose, not the brand: Consider prescribing "estradiol transdermal 0.05 mg/day, apply one patch weekly" rather than "Climara 0.05 mg/day." This gives the pharmacist flexibility to dispense whichever manufacturer's product is in stock.
• Include alternate formulation instructions: If appropriate, note on the prescription that twice-weekly patches or transdermal gel are acceptable substitutes if weekly patches are unavailable.

Strategy 3: Proactively Discuss Alternatives

Don't wait for your patient to call in distress because their pharmacy is out. During routine visits, discuss backup options:

Patch Alternatives

• Vivelle-Dot / Dotti (generic): Twice-weekly estradiol patch, available in 0.025–0.1 mg/day strengths
• Minivelle: Smallest available estradiol patch, twice-weekly application
• Generic estradiol transdermal patches: Multiple manufacturers (Mylan, Noven, others)

Non-Patch Transdermal Alternatives

• Divigel: Estradiol gel in single-dose packets, applied daily to the thigh
• EstroGel: Metered-dose pump gel, applied daily to one arm
• Evamist: Estradiol spray, 1–3 sprays daily to the inner forearm

Oral Option

• Oral estradiol: 0.5–2 mg tablets daily. Most affordable and widely available, though first-pass hepatic metabolism may increase thrombotic risk in susceptible patients.

Document the discussion and the patient's preferred alternative in the chart so you can act quickly if Climara becomes unavailable.

Strategy 4: Leverage Different Pharmacy Channels

Advise patients to explore multiple pharmacy types:

• Independent pharmacies: Often work with multiple wholesalers and may have stock when chains don't
• Mail-order pharmacies: Typically maintain larger inventories; 90-day supplies reduce refill frequency
• Specialty hormone pharmacies: Some compound pharmacies specialize in HRT and may have better access to estradiol products
• Hospital outpatient pharmacies: May have separate supply chains from retail pharmacies

Strategy 5: Address Cost Barriers During Transitions

Switching products during a shortage can create unexpected costs for patients. Be aware of the following:

• Generic estradiol patches: $25–$60 per box (4 patches) — significantly less than brand Climara ($130–$200)
• Insurance formulary position may differ between products — prior authorization may be needed for some alternatives
• Coupon cards (SingleCare, GoodRx) can reduce costs for uninsured or underinsured patients
• Bayer Patient Assistance Foundation (1-866-575-5002) provides free Climara to qualifying patients

For detailed cost information and savings programs, see our provider's guide to helping patients save money on Climara.

Strategy 6: Monitor Patients After Switching

When transitioning patients to a different estradiol product:

• Check serum estradiol levels 4–8 weeks after switching to confirm adequate absorption
• Assess symptom control at follow-up — vasomotor symptoms, mood, sleep quality
• Watch for application site reactions if switching between patch brands or from patches to gels
• Reassess bone density monitoring schedule if the patient was using Climara for osteoporosis prevention

Creating a Practice Protocol

Consider developing a standard protocol for your practice to handle medication shortages efficiently:

1. Identify at-risk medications: Climara and other transdermal estradiol products should be on your shortage watch list
2. Pre-authorize alternatives: Document acceptable alternatives in each patient's chart during routine visits
3. Train staff: Ensure clinical staff know to recommend MedFinder and can help patients navigate pharmacy options
4. Set up alerts: Monitor FDA drug shortage updates and manufacturer communications

Provider Resources

• MedFinder for Providers — Real-time pharmacy stock search
• Climara shortage: Clinical overview for prescribers
• Patient-facing shortage update — Share with your patients
• Patient guide to Climara alternatives
• FDA Drug Shortage Database